Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.

Apertura has entered a CRADA with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1).

AstraZeneca and Sino Biopharmaceutical's subsidiary CTTQ have signed an exclusive licence agreement for TQC3721.

Evogene and Tel Aviv University’s BCDD have partnered to expedite small-molecule drug discovery originating from Israeli academic research.

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off mark ...

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.

The FDA is taking action to curb the illicit online trade of unregulated and unapproved ketamine products through a slew of warning letters.

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.